{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T04:25:01Z","timestamp":1692332701420},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Loss of efficacy of hormonal contraceptives is of particular concern for women who are overweight or obese. Only recently have clinical trials started to include overweight and obese women in their study populations, limiting the data available on which to make the best prescribing decisions for hormonal contraceptives for these patients. Other methods, such as the copper or levonorgestrel-containing intrauterine device, the etonogestrel implant, and depot medroxyprogesterone acetate, are preferred over combined oral contraceptives, the transdermal patch, and the vaginal ring.<\/jats:p>","DOI":"10.1097\/01.jaa.0000527709.23569.dc","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T17:50:16Z","timestamp":1514397016000},"page":"11-13","source":"Crossref","is-referenced-by-count":0,"title":["Are hormonal contraceptives less effective in overweight and obese women?"],"prefix":"10.1097","volume":"31","author":[{"given":"Shriya","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230817","article-title":"Prevalence of obesity among adults and youth: United States, 2011-2014","author":"Ogden","year":"2015"},{"issue":"8","key":"R2-20230817","first-page":"CD008452","article-title":"Hormonal contraceptives for contraception in overweight or obese women","author":"Lopez","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"R3-20230817","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.contraception.2015.07.016","article-title":"Effect of obesity on the effectiveness of hormonal contraceptives: an individual participant data meta-analysis","volume":"92","author":"Yamazaki","year":"2015","journal-title":"Contraception"},{"issue":"1","key":"R4-20230817","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.contraception.2016.08.003","article-title":"Clarification of contraceptive drug pharmacokinetics in obesity","volume":"95","author":"Jusko","year":"2017","journal-title":"Contraception"},{"issue":"4","key":"R5-20230817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6504a1","article-title":"U.S. selected practice recommendations for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"R7-20230817","article-title":"Contraception counseling for obese women. UpToDate","author":"Edelman"},{"issue":"11","key":"R8-20230817","first-page":"369","article-title":"Levonorgestrel intrauterine device use in overweight and obese women","volume":"74","author":"Saito-Tom","year":"2015","journal-title":"Hawaii J Med Public Health"},{"issue":"3","key":"R10-20230817","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.contraception.2015.11.005","article-title":"Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year","volume":"93","author":"Morrell","year":"2016","journal-title":"Contraception"},{"issue":"1","key":"R11-20230817","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/AOG.0b013e318259565a","article-title":"Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women","volume":"120","author":"Xu","year":"2012","journal-title":"Obstet Gynecol"},{"issue":"6","key":"R12-20230817","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.contraception.2010.01.021","article-title":"Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously","volume":"81","author":"Segall-Gutierrez","year":"2010","journal-title":"Contraception"},{"issue":"3","key":"R14-20230817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6503a1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"R15-20230817","article-title":"Infertility and contraception","author":"Hall","year":"2017","journal-title":"Harrison's Principles of Internal Medicine"},{"issue":"2","key":"R16-20230817","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.contraception.2012.10.008","article-title":"Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users","volume":"87","author":"Edelman","year":"2013","journal-title":"Contraception"},{"issue":"6","key":"R17-20230817","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.contraception.2010.01.016","article-title":"Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women","volume":"81","author":"Westhoff","year":"2010","journal-title":"Contraception"},{"issue":"3","key":"R19-20230817","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/AOG.0b013e31828317cc","article-title":"Contraceptive failures in overweight and obese combined hormonal contraceptive users","volume":"121","author":"McNicholas","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"2","key":"R20-20230817","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.contraception.2016.10.010","article-title":"Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review","volume":"95","author":"Dragoman","year":"2017","journal-title":"Contraception"},{"issue":"3","key":"R21-20230817","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.contraception.2014.04.018","article-title":"Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol\/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles","volume":"90","author":"Westhoff","year":"2014","journal-title":"Contraception"},{"issue":"2 suppl 2","key":"R22-20230817","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0015-0282(01)03275-7","article-title":"Contraceptive efficacy and cycle control with the Ortho Evra\/Evra transdermal system: the analysis of pooled data","volume":"77","author":"Zieman","year":"2002","journal-title":"Fertil Steril"},{"issue":"4","key":"R23-20230817","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.contraception.2012.12.001","article-title":"Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women","volume":"87","author":"Dragoman","year":"2013","journal-title":"Contraception"},{"issue":"5","key":"R24-20230817","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2217\/WHE.13.41","article-title":"Obesity and hormonal contraceptive efficacy","volume":"9","author":"Robinson","year":"2013","journal-title":"Womens Health (Lond)"},{"issue":"4","key":"R25-20230817","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.contraception.2011.02.009","article-title":"Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel","volume":"84","author":"Glasier","year":"2011","journal-title":"Contraception"},{"issue":"2","key":"R26-20230817","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.contraception.2014.11.001","article-title":"Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception","volume":"91","author":"Kapp","year":"2015","journal-title":"Contraception"},{"key":"R27-20230817","article-title":"Contraception","author":"Shrader","year":"2017","journal-title":"Pharmacotherapy: A Pathophysiologic Approach"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01720610-201801000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:51:06Z","timestamp":1692319866000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01720610-201801000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000527709.23569.dc","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}